ABCELLERA BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.76 USD | +3.58% |
|
-2.84% | -34.15% |
| 11/03 | AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases | MT |
| 11/03 | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions | CI |
Chart calendar AbCellera Biologics Inc.
ee371ce466aaaea7aaaa12e59ef3053a.PxNgLGpelm8EYTw3mXZXHFNSE9uUJXFIgd9QnVkRWfY.DUoZYi4r9Ro8JHBx6yEcWzkaYZymTRog-7llxyp9PLtsJVN4IjylXWIWBA~9845036073943feb8a15162dac2c8cbf
Upcoming events on AbCellera Biologics Inc.
Past events on AbCellera Biologics Inc.
| 16/04/2024 07:30 pm | Bloom Burton Healthcare Conference |
| 10/04/2024 02:00 am | American Association for Cancer Research Meeting - Abstract # 6359 |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract #1868 |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract # 1859 |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract # 2373 |
| 20/03/2024 08:45 pm | KeyBanc Capital Markets Life Sciences and MedTech Investor Forum |
| 06/03/2024 01:20 am | TD Cowen Health Care Conference |
| 21/02/2024 03:30 am | Q4 2023 Earnings Call |
| 21/02/2024 02:35 am | Q4 2023 Earnings Release |
| 11/01/2024 03:45 am | JPMorgan Healthcare Conference |
| 30/11/2023 08:00 pm | Piper Sandler Healthcare Conference |
| 14/11/2023 10:00 pm | Jefferies London Healthcare Conference |
| 03/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 1395 |
| 03/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 1367 |
| 03/11/2023 02:30 am | Q3 2023 Earnings Call |
| 03/11/2023 01:35 am | Q3 2023 Earnings Release |
| 04/08/2023 02:30 am | Q2 2023 Earnings Call |
| 04/08/2023 01:35 am | Q2 2023 Earnings Release |
| 15/06/2023 09:30 pm | Annual General Meeting |
| 14/06/2023 01:50 am | Goldman Sachs Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 11,6 | 233 213 9.51% | 375 354 5.88% | 485 518 -6.24% | 38,0 38,1 -0.27% | 47,8 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 161 163 -1.14% | 219 192 13.84% | 244 322 -24.16% | -213 -199 -7.2% | -217 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | 156 167 -6.6% | 204 189 7.9% | 217 268 -19.1% | -237 -226 -5.07% | -240 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | 158 174 -9.28% | 219 205 7.1% | 239 281 -14.81% | -174 -171 -1.6% | -208 |
|
Net income Million USD | Released Forecast Spread | 0,00 | 119 136 -12.6% | 153 151 1.37% | 159 183 -13.27% | -146 -141 -4.09% | -190 |
|
EPS USD | Released Forecast Spread | -0,15 | 0,45 0,60 -25.25% | 0,48 0,50 -4.48% | 0,50 0,59 -15.43% | -0,51 -0,47 -7.94% | -0,61 |
| Announcement Date | 05/10/20 | 29/03/21 | 24/02/22 | 21/02/23 | 20/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 139 122 14.16% | 317 220 44.06% | 45,9 53,6 -14.32% | 101 83,4 21.62% | 21,5 50,8 -57.59% | 12,2 12,1 0.69% | 10,1 12,2 -17.65% | 6,60 11,5 -42.5% | 9,20 9,32 -1.23% | 10,9 | 11,5 | 12,0 | 13,0 | 19,2 |
|
EBITDA Million USD | Released Forecast Spread | 85,5 58,1 47.23% | 229 38,2 498.87% | -3,50 -24,1 85.45% | 42,9 32,0 33.97% | -24,0 -13,5 -78.14% | -59,4 -41,4 -43.38% | -55,7 -41,6 -33.93% | -52,2 | -54,2 | -51,6 | -48,7 | -41,3 | ||
|
EBIT Million USD | Released Forecast Spread | 81,6 66,5 22.73% | 225 165 36.4% | -8,40 -7,88 -6.51% | 37,7 22,4 68.64% | -37,8 -6,30 -499.31% | -64,9 -46,9 -38.4% | -51,4 -46,1 -11.42% | -54,9 -51,6 -6.35% | -66,1 -53,9 -22.53% | -60,3 | -59,8 | -59,1 | -59,3 | -55,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 84,7 75,5 12.25% | 231 165 40.1% | -6,89 -5,63 -22.34% | 46,6 24,2 92.91% | -31,4 -9,09 -245.57% | -48,1 -39,0 -23.56% | -38,0 -40,5 6.08% | -39,3 -41,9 6.33% | -48,6 -45,7 -6.3% | -51,9 | -52,3 | -51,8 | -52,3 | -55,6 |
|
Net income Million USD | Released Forecast Spread | 59,9 61,0 -1.7% | 169 128 32.02% | -6,79 -6,99 2.96% | 26,6 15,6 70.38% | -29,9 -5,10 -486.48% | -40,1 -36,9 -8.59% | -30,5 -38,7 21.14% | -28,6 -38,5 25.77% | -47,2 -41,2 -14.45% | -48,1 | -48,4 | -47,6 | -49,1 | -55,6 |
|
EPS USD | Released Forecast Spread | 0,19 0,19 0.89% | 0,54 0,38 40.52% | -0,02 -0,02 -27.31% | 0,08 0,05 66.67% | -0,10 -0,01 -700% | -0,14 -0,13 -10.52% | -0,11 -0,12 10.47% | -0,10 -0,13 21.57% | -0,16 -0,13 -24.27% | -0,15 | -0,15 | -0,15 | -0,15 | -0,15 |
| Announcement Date | 24/02/22 | 10/05/22 | 09/08/22 | 08/11/22 | 21/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 20/02/24 | - | - | - | - | - |
More events
Past sector events for AbCellera Biologics Inc.
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ABCL Stock
- Calendar AbCellera Biologics Inc.
